ImmunoGen, Novartis ink license agreement
Friday, October 11, 2013
This is the second license to be taken by Novartis under a 2010 agreement between the companies. For each license, ImmunoGen receives an upfront payment and milestone payments potentially totaling approximately $200 million plus royalties on sales. Novartis is responsible for the development, manufacturing and marketing of any products resulting from the license.